

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.

36731S-000001/US

APPLICATION NO.

10/786,907

APPLICANT

Bjarne Bogen

FILING DATE

February 25, 2004

GROUP

1643

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
1.	/LB/	Arya Biragyn et al.; "Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity"; Nature Biotechnology; Volume 17, March 1999, pages 253-258.
2.		Andreas Pluckthun et. Al.; "New protein engineering approaches to multivalent and bispecific antibody fragments"; Immunotechnology, Volume 3, 1997, pages 83-105.
3.		Hsin-Wei Chen et. Al.; "Linkage of CD40L to a self-tumor antigen enhances the anti tumor immune responses to dendritic cell-based treatment"; Cancer Immunol Immunother, Volume 51, 2002, pages 341-348.
4.		Hsing-I Huang et. al.; "Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand"; Int. J. Cancer, Volume 108, 2004, pages 696-703.
5.		Tzu-Hsuan Huang et. al.; "Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen"; Blood, Volume 96, No.12, December 2000, pages 3663-3670.
6.		Jitra, Kriangkum et. al.; "Bispecific and bifunctional single chain recombinant antibodies"; Biomolecular Engineering, Volume 18, 2001, pages 31-40.
7.		Annemiek B. van Spriel et. al.; "Immunotherapeutic perspective for bispecific antibodies"; Immunology today, Volume 21, No. 8, August 2000, pages 391-396.
8.		Hennie R. Hoogenboom; "Mix and match: Building manifold binding sites"; Nature Biotechnology, Volume 15, February 1997, pages 125-226.
9.		Shi-zhen Hu et. al.; "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3), Which Exhibits Rapid, High-Level Targeting of Xenografts"; Cancer Research, Volume 56, July 1996, pages 3055-3061.
10.		Arya Biragyn et. al.; "Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by Beta-Defensin 2"; Science, Volume 298, November 2002, pages 1025-1029.
11.		E. Lunde et. al.; "Troybodies and Pepbodies"; Biochemical Society Transactions, Volume 30, Part 4, 2002, pages 500-506.
12.		Elin Lunde et. al.; "Troy-bodies"; Intern. Rev. Immunol., Volume 20, 2001,; Recombinant Antibodies that Target T Cell Epitopes to Antigen Presenting Cells", pages 647-673.
13.		Adelchi Ruffini et. al.; "Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines", Haematologica, Volume 87, 2002, Pier, pages 989-1001.

Examiner: /Lynn Bristol/

Date Considered:

10/25/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.